Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NextEra Energy, Inc. (NEE) vs Novartis AG (NVS) Price & Performance

NextEra Energy, Inc.Trade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

NextEra Energy, Inc. vs Novartis AG — how do they compare? NextEra Energy, Inc. trades at $83.01 (market cap $174.87B), while Novartis AG trades at $138.16 (market cap $262.64B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.

NEENVS
Market Cap
$174.87B$262.64B
Sector
UtilitiesHealth
52-Week High
$97.88$168.62
52-Week Low
$69.83$121.80
Enterprise Value
$282.20B$303.97B
Dividend Yield
2.97%3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NextEra Energy, Inc.

NextEra Energy (NEE) trades at $83.83, up 0.48% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with Q1 and Q2 2026 earnings beats, a 32.4% net income margin, and recent positive developments including a $1.9 billion DOE loan for nuclear plant restart. Cash flow improved to $1.6B net in 2025, though debt-to-asset ratio rose to 47.6%.

Outlook remains positive with 66.7% analyst buy ratings and a $100.20 consensus price target offering 19.5% upside. Key risks include rising leverage, competitive pressures, and execution of growth projects. The stock presents a growth opportunity in renewable energy with institutional backing, balanced by macroeconomic and regulatory uncertainties.

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NextEra Energy, Inc.

NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.

Read more on NEE

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS